Biologically, we established that MDM2-mediated TOP2β degradation increases cancer cell survival, since its inhibition by RG7112 decreases the survival of lung cancer cells synergistically with VP-16 treatment, resulting in increased apoptosis and higher sensitivity to VP-16 treatment (Fig. 7). Here, MDM2 is linked to lung cancer.